Coronary artery calcium and cardiovascular risk factors analysis after radiotherapy for breast cancer (the CLARIFIER: a gender-based preventive medicine study)

乳腺癌放疗后冠状动脉钙化和心血管危险因素分析(CLARIFIER:一项基于性别的预防医学研究)

阅读:2

Abstract

INTRODUCTION: Patients receiving thoracic radiation (RT) are at increased risk for heart disease. Coronary artery calcium (CAC) is an independent risk factor for cardiac events. AIM: The aim of this prospective, joint-institution, study was to analyze the relationship between cardiovascular risk factors (CVRF) known before breast cancer diagnosis and treatment, and the risk of developing coronary events in women undergoing adjuvant breast radiotherapy by measuring CAC. METHODS: Women (n = 92) diagnosed with early-stage breast cancer between 2010 and 2016 were enrolled and underwent cardiologic clinical assessment and coronary CT-scan for CAC score analysis, at least 5 years after RT. RESULTS: Data obtained from 91/92 patients, showed a 36.2% incidence of pathologic Agatston CAC score, independent of the irradiated breast side. After grouping patients according to the total number of CVRF [group 1, n = 55 (60.4%): 0-2 CV risk factors; group 2, n = 36 (39.6%): 3-5 CV risk factors] significant differences were observed in CAC scores. Normal CAC scores (Agatston 0) were recorded in 70.9% in group 1 vs. 41.7% in group 2 (p = 0.005), while CAC-3 (Agatston ≥ 300) in 11.1% of group 2 only (p = 0.02), corresponding to clinical evidence of coronary disease. The risk of cardiac events was associated with increased age, early menopause, hypertension, high cholesterol levels, and smoking habits at the time of RT. CONCLUSION: This study helps to identify women at high-risk for cardiovascular events before RT and implement the best possible prevention of late post cancer treatment events. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, Identifier (NCT05775822).

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。